Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 19, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) rather than a financial performance report.
Key Financial Metrics
The filing text does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the transaction price for American Depositary Shares (ADSs), which was $41.81 per share.
Material Changes and Transactions
The filing details two specific transactions executed on April 18, 2017, involving the re-investment of dividends paid on April 13, 2017, under the Company's 2009 Performance Share Plan. These transactions resulted in an increase in notional interest in ADSs for the following executives:
- Mr. B McNamara (CEO, GSK Consumer Healthcare): Acquired an aggregated volume of 1,246.083 ADSs.
- Mr. D E Troy (SVP & General Counsel): Acquired an aggregated volume of 2,673.456 ADSs.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, outlook, risk factors, or contingencies. It is strictly a regulatory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transactions were non-discretionary dividend re-investments under the 2009 Performance Share Plan.
- The share price at the time of transaction was $41.81.
- The filing involves two senior executives: the CEO of Consumer Healthcare and the SVP & General Counsel.
- No financial performance data is included in this specific document.